What are the weight gain risks associated with Vraylar (cariprazine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Weight Gain Risk with Vraylar (Cariprazine)

Vraylar (cariprazine) is associated with minimal weight gain risk compared to other atypical antipsychotics, with mean weight increases of approximately 0.5-1 kg in short-term trials and 1.7-2.5 kg in long-term studies, making it one of the more weight-neutral options in its class.

Weight Gain Profile by Indication

Schizophrenia (Adults)

  • Short-term (6 weeks): Mean weight change of +0.5 kg at modal doses of 3-6 mg/day 1
  • Long-term: Mean weight increases of 1.2 kg at 12 weeks, 1.7 kg at 24 weeks, and 2.5 kg at 48 weeks 1
  • Only 1% of patients experienced ≥7% weight gain (clinically significant threshold) 1

Bipolar Disorder (Adults)

  • Mania trials (3 weeks): Mean weight change of +0.5 to +0.6 kg 1
  • Depression trials (6-8 weeks): Mean weight change of +0.4 to +0.7 kg 1
  • Only 1-3% of patients experienced ≥7% weight gain 1

Major Depressive Disorder (Adjunctive Treatment)

  • 6-week trials: Mean weight change of +0.7 kg 1
  • 8-week trials: Mean weight change of +0.9 kg 1
  • Long-term (26 weeks): Mean weight change of +1.7 kg 1
  • Only 2-3% of patients experienced ≥7% weight gain 1

Real-World Evidence

Recent real-world data provides additional context beyond clinical trials:

  • Annual weight trajectory: Patients gained an estimated +0.91 kg/year during cariprazine treatment, compared to +3.55 kg/year before starting cariprazine 2
  • Retrospective analysis: Average predicted weight change was +2.4 kg overall, with +0.8 kg at 3 months, +1.1 kg at 6 months, and +1.4 kg at 12 months 3
  • Clinically significant changes: 82.8% of patients did not experience ≥7% weight gain, and 90.5% did not experience ≥7% weight loss 3

Comparative Context

Cariprazine ranks among the most weight-neutral atypical antipsychotics, positioned favorably alongside ziprasidone, lurasidone, and aripiprazole 4, 5. The Endocrine Society guidelines specifically recommend using weight-neutral antipsychotic alternatives when clinically indicated 4.

For comparison, other atypical antipsychotics show substantially higher weight gain:

  • Olanzapine: 3.8-16.2 kg (30% with ≥7% weight gain)
  • Clozapine: 0.9-9.5 kg
  • Risperidone: 1.9-7.2 kg (14% with ≥7% weight gain)
  • Quetiapine: 2.3-6.1 kg (16% with ≥7% weight gain)
  • Aripiprazole: 0-4.4 kg 4

Metabolic Profile

Beyond weight, cariprazine demonstrates a favorable metabolic profile:

  • Glucose metabolism: Small increases in fasting glucose (6.6-7.2 mg/dL) were observed, slightly higher than placebo 6. However, real-world data showed HbA1c levels decreased during treatment (-0.2%/year) 3
  • Lipid parameters: Minimal impact on cholesterol and triglycerides. Real-world data showed triglycerides decreased (-0.7 mg/dL/year) during treatment 3
  • Most patients (90.2%) did not shift from normal/borderline to high total cholesterol 3

Pediatric Populations

Schizophrenia (Ages 13-17)

  • Mean weight change: +2.4 kg in long-term studies
  • Age- and sex-adjusted z-score change: +0.1 SD (not clinically significant, as <0.5 SD is the threshold) 1

Bipolar I Disorder (Ages 10-17)

  • Mean weight change: +3.1 kg in long-term studies
  • Age- and sex-adjusted z-score change: +0.2 SD
  • 14.6% had z-score increase ≥0.5 SD (clinically significant) 1

Clinical Monitoring Recommendations

Based on the FDA label and clinical guidelines:

  1. Baseline assessment: Obtain weight, BMI, fasting glucose, and lipid panel before initiating cariprazine 1

  2. Regular monitoring: Weigh patients regularly during treatment, particularly in the first 3-6 months when weight changes are most likely to occur 4

  3. Long-term surveillance: Monitor fasting glucose and lipids periodically during long-term treatment 1

  4. Delayed onset consideration: Adverse reactions, including metabolic changes, may first appear several weeks after initiation due to accumulation of cariprazine and its active metabolites 1

Important Caveats

  • Individual variability: While population-level data shows minimal weight gain, some patients may experience more substantial changes
  • Dose relationship: No clear dose-dependent relationship with weight gain was observed in clinical trials 1
  • Comparison to baseline: Real-world data suggests patients may actually gain less weight on cariprazine than they were gaining before treatment initiation 2
  • Shared decision-making: Guidelines recommend discussing quantitative weight gain estimates with patients when selecting antipsychotic therapy 4

References

4
Guideline

pharmacological management of obesity: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

5
Guideline

practical use of pharmacotherapy for obesity.

Gastroenterology, 2017

Related Questions

Is temperature dysregulation a normal side effect of Vraylar (cariprazine)?
Can an SNRI be safely combined with Vraylar (cariprazine), and what dosing and monitoring considerations are recommended?
Can Vraylar (cariprazine) be taken at night?
What is the average weight gain associated with Vraylar (cariprazine)?
Does Vraylar (cariprazine) cause weight gain?
A patient began oral bioidentical hormone replacement therapy with progesterone 100 mg and estradiol 1 mg 16 days ago and experienced a brief, resolved dizziness spell; what is the appropriate management?
For a typical adult requiring long‑term antidepressant therapy, how should antidepressants be ranked according to overall tolerability and ease of discontinuation?
What is the diagnosis and recommended management for a boy kept in a sterile bubble due to severe combined immunodeficiency (SCID)?
In a patient with a junctional rhythm, is it safe to switch metoprolol to nebivolol (Bystolic)?
What first‑line antihypertensive medication should be used for a patient with hypertension who is allergic to angiotensin‑II receptor blockers (ARBs)?
What are the causes of overweight and diarrhea in infants?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question